Passage Bio, Inc.
NASDAQ:PASG
Overview | Financials
Company Name | Passage Bio, Inc. |
Symbol | PASG |
Currency | USD |
Price | 0.829 |
Market Cap | 51,205,092 |
Dividend Yield | 0% |
52-week-range | 0.451 - 1.79 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. William Chou M.D. |
Website | https://www.passagebio.com |
An error occurred while fetching data.
About Passage Bio, Inc.
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD